GlassScriptPhysician profile
Rudolf D Bucci
NPI 1003954140
$6,345.25
in general payments reported to CMS, 2019-2025
32 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $1,648 · 2023: $1,102 · 2024: $1,219 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.94 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,378.64 | 2021-2025 | Ozempic, Wegovy, Sogroya |
| Mannkind Corporation | $908.67 | 2021-2024 | Afrezza |
| Lilly USA, LLC | $829.06 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $385.24 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $384.84 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $333.87 | 2021-2025 | Breztri, Airsupra, Lokelma |
| Insulet Corporation | $301.62 | 2024-2025 | Omnipod |
| Abbvie INC. | $300.07 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.42 | 2022-2025 | Jardiance |
| Grifols USA, LLC | $161.94 | 2021-2022 | |
| Dexcom, INC. | $152.19 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $118.28 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $101.02 | 2023-2025 | Tepezza, Repatha |
| Merck Sharp & Dohme LLC | $96.03 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $92.38 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $86.01 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $83.63 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $77.14 | 2021-2022 | |
| Abbott Laboratories | $54.10 | 2025 | Freestyle Libre 3 |
| Amphastar Pharmaceuticals, INC. | $46.23 | 2024-2025 | |
| Medtronic, INC. | $44.03 | 2022-2023 | Minimed 780g |
| Corcept Therapeutics | $35.24 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $32.42 | 2021-2024 | Crysvita |
| Neurocrine Biosciences, INC. | $30.13 | 2025 | |
| Inspire Medical Systems, INC. | $29.17 | 2025 | Inspire |
| Pfizer INC. | $26.73 | 2022 | |
| Sequel Med Tech, LLC | $21.48 | 2025 | Twiist |
| Eisai INC. | $19.19 | 2021 | |
| Daiichi Sankyo INC. | $18.66 | 2021 | |
| Esperion Therapeutics, INC. | $13.69 | 2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.31 | 2023 | Xifaxan |
| Cequr Corporation | $7.82 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudolf Bucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.